Abstract
Background: Repeated administrations of insulin injection on daily basis evoke pain and numerous complications with adverse effects on the diabetic patients’ life quality. Moreover, wearing insulin pump is also associated with several problems of diabetic ketoacidosis, catheter site infection, contact dermatitis and high cost.
Method: We have developed an in situ gel system, consisting of insulin-loaded liposomes dispersed within a thermoreversible gel (Pluronic® F127 gel), which increases the duration of insulin action for the treatment of diabetes. Vesicular phospholipid gel technique was used to encapsulate the insulin into liposomes.
Results: The resulting liposomal gel formulation had a longer drug-release period in vitro than a free insulin solution or liposomes and Pluronic® F127 gel individually. Furthermore, the addition of liposomes to the Pluronic® F127 gel improved the stability of the encapsulated insulin at a physiological temperature. In vivo study was performed to investigate the bioactivity and absorption of insulin released from the liposomal gel and other formulations. The liposomal gel released insulin into the bloodstream continuously for up to 7 days and significantly enhanced drug bioavailability compared to insulin released from liposomes or Pluronic® F127 gel individually. Blood glucose levels were reduced for up to 4 days. Histology data demonstrated excellent biocompatibility of the Pluronic® F127 gel-based delivery systems, with no observable inflammatory response in rat subcutaneous tissues.
Conclusion: Obtained results show that the insulin-loaded liposomes dispersed within Pluronic® F127 gel can be used as a long-acting drug delivery system, and replacement for conventional insulin therapy.
Keywords: Insulin, Liposome, thermoreversible gel, controlled release, subcutaneous administration, diabetes mellitus.
Current Pharmaceutical Design
Title:Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel
Volume: 23 Issue: 39
Author(s): Xiaoyu Chen, Blenda Chi Kwan Wong, Hubiao Chen, Shiping Zhang, Zhaoxiang Bian, Ge Zhang, Congcong Lin, Muhammad Kashif Riaz, Deependra Tyagi, Aiping Lu*Zhijun Yang*
Affiliation:
- School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong,China
- School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong,China
Keywords: Insulin, Liposome, thermoreversible gel, controlled release, subcutaneous administration, diabetes mellitus.
Abstract: Background: Repeated administrations of insulin injection on daily basis evoke pain and numerous complications with adverse effects on the diabetic patients’ life quality. Moreover, wearing insulin pump is also associated with several problems of diabetic ketoacidosis, catheter site infection, contact dermatitis and high cost.
Method: We have developed an in situ gel system, consisting of insulin-loaded liposomes dispersed within a thermoreversible gel (Pluronic® F127 gel), which increases the duration of insulin action for the treatment of diabetes. Vesicular phospholipid gel technique was used to encapsulate the insulin into liposomes.
Results: The resulting liposomal gel formulation had a longer drug-release period in vitro than a free insulin solution or liposomes and Pluronic® F127 gel individually. Furthermore, the addition of liposomes to the Pluronic® F127 gel improved the stability of the encapsulated insulin at a physiological temperature. In vivo study was performed to investigate the bioactivity and absorption of insulin released from the liposomal gel and other formulations. The liposomal gel released insulin into the bloodstream continuously for up to 7 days and significantly enhanced drug bioavailability compared to insulin released from liposomes or Pluronic® F127 gel individually. Blood glucose levels were reduced for up to 4 days. Histology data demonstrated excellent biocompatibility of the Pluronic® F127 gel-based delivery systems, with no observable inflammatory response in rat subcutaneous tissues.
Conclusion: Obtained results show that the insulin-loaded liposomes dispersed within Pluronic® F127 gel can be used as a long-acting drug delivery system, and replacement for conventional insulin therapy.
Export Options
About this article
Cite this article as:
Chen Xiaoyu , Wong Chi Kwan Blenda , Chen Hubiao , Zhang Shiping, Bian Zhaoxiang , Zhang Ge, Lin Congcong , Riaz Kashif Muhammad, Tyagi Deependra , Lu Aiping *, Yang Zhijun*, Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170509123844
DOI https://dx.doi.org/10.2174/1381612823666170509123844 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Diagnosis and New Approaches in the Therapy of Gestational Diabetes Mellitus
Current Diabetes Reviews The Central Nervous System as a Promising Target to Treat Diabetes Mellitus
Current Topics in Medicinal Chemistry Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Self-management of Diabetes in Children and Young Adults Using Technology and Smartphone Applications
Current Diabetes Reviews Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Insulin Therapy: Going The "Smarter" Way
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Risk Factors for Suicide – An Alternative View
CNS & Neurological Disorders - Drug Targets Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Impact of Glycemic Variability and Hypoglycemia on the Mortality and Length of Hospital Stay among Elderly Patients in Brazil
Current Diabetes Reviews Decreased Plasma Level of Lipoprotein Lipase Predicted Verbal Disfluency in Chinese Type 2 Diabetes Mellitus Patients with Early Cognitive Deficits
Current Alzheimer Research